Patients


Learn More

Physicians


Learn More

Investors


Learn More

ABOUT ESPERO (Espero BioPharma)


We named our company Espero because it means hope. And that’s what we seek to provide everyone who takes our innovative cardiovascular medicines. Hope for improved health and hope for a better tomorrow.

Espero is a biopharmaceutical company focusing on the late-stage development and commercialization of medicines to treat cardiovascular diseases, the leading cause of death worldwide. Recently, Espero merged with Armetheon, Inc., a privately-held, specialty pharmaceutical company developing innovative medicines, initially in thrombosis (tecarfarin) and cardiac arrhythmias (budiodarone). The Company also markets and distributes three in-market standard of care cardiovascular drugs: GoNitroTM (nitroglycerin) sublingual powder (antianginal), Durlaza® (aspirin) Extended Release Capsules, and Nitrolingual® Pumpspray (antianginal).


News


Events


Upcoming Events

  1. J.P. MORGAN 36TH ANNUAL HEALTHCARE CONFERENCE

    January 8, 2018 - January 10, 2018
  2. BIO CEO INVESTOR CONFERENCE

    February 12, 2018 - February 13, 2018
  3. EMS TODAY THE JEMS CONFERENCE AND EXPOSITION

    February 22, 2018 - February 24, 2018
  4. ACC.18 AMERICAN COLLEGE OF CARDIOLOGY CONFERENCE 67TH ANNUAL SCIENTIFIC SESSION AND EXPO

    March 10, 2018 - March 12, 2018



GoNitro™

(Nitroglycerin Sublingual Powder)

GONITROLearn More

The FDA recently approved GoNitro™ (nitroglycerin) sublingual powder, the first and only short-acting nitrate in a stabilized crystal granule form available in single dose packets.

Important Safety Information



Nitrolingual®

(Nitroglycerin Spray)

Learn More

Nitrolingual Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
Important Safety Information



DURLAZA®

(Aspirin)

Learn More

DURLAZA (aspirin) Extended Release Capsules, for oral use, is indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina; and reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.
Important Safety Information



Tecarfarin

(Anti-Coagulant)

Learn More

Espero Biopharma’s late-clinical stage oral anticoagulant candidate – Tecarfarin – addresses a major unmet need – a medication with potentially fewer adverse and fatal drug reactions and expected compatibility with treatment plans for patients with prosthetic heart valves.


Budiodarone

(Anti-Arrhythmia)

Learn More

Budiodarone is a clinical-stage oral drug candidate that is being investigated for its potential to suppress life-threatening ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs). Budiodarone reduced AF burden in a dose-dependent fashion with up to 75% reduction in the highest dose group in a Phase 2 study with 72 patients with atrial fibrillation.

Educating the Community


As we advance the clinical stages of testing for tecarfarin and budiodarone, we are sharing our story with healthcare providers at appropriate peer-reviewed forums.


Learn More Today


As we complete the late clinical stage for Tecarfarin, we’d like to share our story with healthcare providers. Physicians and their patients could benefit from Espero Biopharma’s novel drug development approach. Please contact us for more information.


Contact Us


Important Safety Information


GoNitro™ (nitroglycerin) sublingual powder should not be used if you are taking medications for erectile dysfunction, such as avanafil, sildenafil, tadalafil, or vardenafil. Using GoNitro with these products may cause low blood pressure (hypotension), fainting, or heart attack.

Do not use GoNitro if you are taking soluble guanylate cyclase (sGC) stimulators, such as riociguat. Using GoNitro with these products may cause low blood pressure (hypotension).

GoNitro should not be used if you have anemia.

GoNitro should not be used in patients with increased intracranial pressure. Talk to your doctor if you had a cerebral hemorrhage or traumatic brain injury before taking GoNitro.

GoNitro should not be used if you have acute circulatory failure or shock.

GoNitro should not be used if you are allergic to nitroglycerin, other nitrates or nitrites or any excipient.

You might develop a tolerance to this drug or to other nitrates and nitrites. Only the smallest number of doses required for effective relief of the acute angina attack or prevention of an attack should be used.

You should use nitroglycerin with caution in the early days after a heart attack and it may aggravate the angina caused by a condition known as hypertrophic cardiomyopathy. Increased hypotension, mainly when standing upright, may occur even with small doses of nitroglycerin and may result in slow heart beat and increased angina. It should be used with caution if you are dehydrated due to drug therapy or if you have low blood pressure.

Headache is the most reported side effect and may be severe and persistent. Other side effects that have been reported are dizziness, numbness and tingling of the skin, skin scaling and rashes, drowsiness, nausea, increased heart rate.

Click here for full Prescribing Information.

Nitrolingual Pumpspray should not be used if you are allergic to nitroglycerin or if you are using medications for erectile dysfunction such as avanafil, sildenafil, vardenafil, or tadalafil. Using Nitrolingual Pumpspray with these products may cause low blood pressure (hypotension), fainting, or heart attack.

Nitrolingual Pumpspray should not be used if you have anemia.

Nitrolingual Pumpspray should not be used in patients with increased intracranial pressure. Talk to your doctor if you had a cerebral hemorrhage or traumatic brain injury before taking Nitrolingual Pumpspray.

You might develop a tolerance to this drug or to other nitrates and nitrites. Only the smallest number of doses required for effective relief of the acute angina attack should be used.

You should use nitroglycerin with caution in the early days after a heart attack and it may aggravate the angina caused by a condition known as hypertrophic cardiomyopathy. Increased hypotension, mainly when standing upright, may occur even with small doses of nitroglycerin and may result in slow heart beat and increased angina. It should be used with caution if you are dehydrated due to drug therapy or if you have low blood pressure.

Headache is the most reported side effect and may be severe and persistent. Other side effects that have been reported are dizziness, numbness and tingling of the skin, drowsiness, nausea, increased heart rate.

Click here for Full Prescribing Information.
Talk to your healthcare provider to see if Nitrolingual is right for you.

DURLAZA® (aspirin) Extended-Release Capsules 162.5 mg is indicated:

  • to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina;
  • to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.

Limitation of Use: Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention).

Important Safety Information

Contraindications: DURLAZA is contraindicated in patients with a hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps. DURLAZA may cause severe urticaria, angioedema, or bronchospasm.

Warnings and precautions:

  • DURLAZA increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk for bleeding.
  • DURLAZA may cause gastric ulceration and bleeding. Avoid DURLAZA in patients with active peptic ulcer disease.
  • DURLAZA can cause fetal harm when administered to a pregnant woman, including low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Avoid DURLAZA in the third trimester of pregnancy.

Adverse reactions: The following adverse reactions have been reported for products containing low dose aspirin:

  • Central Nervous System: Agitation, cerebral edema, coma, confusion, dizziness, headache, lethargy, seizures;
  • Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis;
  • Gastrointestinal: Dyspepsia, hepatic enzyme elevation, hepatitis, Reye’s Syndrome;
  • Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure.

Drug interactions:

  • Alcohol: Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol.
  • Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia.
  • Anticoagulant and antiplatelets: Increased risk of bleeding.
  • Anticonvulsants: Decreased phenytoin concentration and increased serum valproic acid levels.
  • Methotrexate: Increased risk of bone marrow toxicity.
  • NSAIDs: Increased risk of bleeding. Nonselective NSAIDs may interfere with the antiplatelet effect of DURLAZA.

Use in specific populations:

  • Pregnancy: Avoid use during the third trimester.
  • Hepatic Impairment: Avoid use in patients with severe impairment.
  • Renal Impairment: Avoid use in patients with GFR <10mL/min.

Click here for DURLAZA Full Prescribing Information.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.